Thompson Davis & CO. Inc. Invests $1.26 Million in Henry Schein, Inc. $HSIC

Thompson Davis & CO. Inc. bought a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 17,270 shares of the company’s stock, valued at approximately $1,262,000.

Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in Henry Schein by 6.5% in the 1st quarter. JPMorgan Chase & Co. now owns 6,373,036 shares of the company’s stock valued at $436,489,000 after purchasing an additional 390,399 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Henry Schein by 4.8% in the first quarter. Dimensional Fund Advisors LP now owns 2,240,933 shares of the company’s stock valued at $153,480,000 after buying an additional 103,384 shares during the last quarter. Burgundy Asset Management Ltd. boosted its position in Henry Schein by 33.9% during the first quarter. Burgundy Asset Management Ltd. now owns 2,235,429 shares of the company’s stock worth $153,105,000 after acquiring an additional 566,530 shares during the last quarter. Clarkston Capital Partners LLC raised its holdings in Henry Schein by 0.4% in the 1st quarter. Clarkston Capital Partners LLC now owns 1,751,570 shares of the company’s stock valued at $119,965,000 after acquiring an additional 7,345 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Henry Schein by 1.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,203,676 shares of the company’s stock worth $82,440,000 after purchasing an additional 11,999 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on HSIC shares. Morgan Stanley boosted their price target on shares of Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research report on Wednesday, November 5th. UBS Group decreased their target price on shares of Henry Schein from $75.00 to $70.00 and set a “neutral” rating on the stock in a report on Wednesday, August 6th. Barrington Research set a $79.00 price objective on Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Evercore ISI raised their target price on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Finally, Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Five equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $76.08.

Henry Schein Stock Performance

Shares of HSIC stock opened at $72.82 on Thursday. The company has a market cap of $8.57 billion, a P/E ratio of 23.50, a PEG ratio of 2.06 and a beta of 0.84. The company has a current ratio of 1.41, a quick ratio of 0.78 and a debt-to-equity ratio of 0.51. The firm has a fifty day moving average price of $66.58 and a 200 day moving average price of $68.89. Henry Schein, Inc. has a 12 month low of $60.56 and a 12 month high of $82.49.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.11. The business had revenue of $3.34 billion for the quarter, compared to the consensus estimate of $3.28 billion. Henry Schein had a return on equity of 14.36% and a net margin of 3.05%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Sell-side analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.